Gritstone bio, Inc. (GRTS)
| Previous Close | 2.1700 |
| Open | 2.1500 |
| Bid | 2.1300 x 800 |
| Ask | 2.1400 x 1800 |
| Day's Range | 2.1100 - 2.2150 |
| 52 Week Range | 2.0000 - 14.4200 |
| Volume | |
| Avg. Volume | 1,326,035 |
| Market Cap | 144.134M |
| Beta (5Y Monthly) | 0.37 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0740 |
| Earnings Date | Mar 11, 2022 - Mar 15, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.67 |
- Simply Wall St.
Are Institutions Heavily Invested In Gritstone bio, Inc.'s (NASDAQ:GRTS) Shares?
The big shareholder groups in Gritstone bio, Inc. ( NASDAQ:GRTS ) have power over the company. Generally speaking, as a...
- GlobeNewswire
CORRECTION -- Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update
-- Clinical programs continue progressing, with multiple Phase 2 data catalysts from neoantigen oncology vaccine programs and additional human data evaluating self-amplifying mRNA (samRNA) vaccines against viruses expected over the next 18 months -- -- Recent presentations reinforce expertise in vaccine design and delivery and potential of Gritstone’s platform technologies in oncology and infectious diseases -- -- Cash, cash equivalents, marketable securities and restricted cash of $186.8 millio
- GlobeNewswire
Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update
-- Clinical programs continue progressing, with multiple Phase 2 data catalysts from neoantigen oncology vaccine programs and additional human data evaluating self-amplifying mRNA (samRNA) vaccines against viruses expected over the next 18 months -- -- Recent presentations reinforce expertise in vaccine design and delivery and potential of Gritstone’s platform technologies in oncology and infectious diseases -- -- Cash, cash equivalents, marketable securities and restricted cash of $186.8 millio
